ANOREXIGENIC DRUGS FOR THE TREATMENT OF O BESITY - CHILEAN CLINICAL NUTRITION ASSOCIATION RECOMMENDATIONS

Obesity is highly prevalent and has several adverse effects on health. Its treatment is thus warranted and must aim to modify dietary and ph ysical activity habits. The opinion of this association is that anorex igenic drugs with cathecolaminergic action (diethylpropion, phentermin e, mazindol and phenylpropanolamine) or serotoninergic action (fenfluo ramine and fluoxetine) may be used in moderate or severe obesity (BMI > 30 kg/m(2) after a complete clinical assessment and in the context o f an integral medical treatment. This association recommends a close s urveillance of the use of these drugs, specially when formulated as no n-proprietary prescriptions.